{"id":"W2401647293","doi":"10.1158/2326-6074.cricimteatiaacr15-a029","title":"Abstract A029: Cell-based cancer immunotherapy using tumor presenting cells: A phase II trial with local advance prostate cancer patients","year":2016,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Axela (Canada)","funders":"","keywords":"Immunotherapy; Medicine; Prostate cancer; MHC class I; Cancer research; Cytotoxic T cell; Cancer; Population; Antigen presentation; Cancer immunotherapy; Immunology; T cell; Antigen; Internal medicine; Major histocompatibility complex; Oncology; Immune system; Biology; In vitro","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009958597,0.0009106125,0.001252272,0.0003840158,0.0003484096,0.000728847,0.0005319881,0.001156505,0.004563351],"category_scores_gemma":[0.0004648396,0.0002465853,0.0008875643,0.0003022778,0.0005528969,0.0003791978,0.0002943458,0.002209465,0.0005673114],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002589523,"about_ca_system_score_gemma":0.0006527226,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00040135,"about_ca_topic_score_gemma":0.000723997,"domain_scores_codex":[0.9997061,0.000143652,0.00001155446,0.00004863663,0.00003493743,0.00005511526],"domain_scores_gemma":[0.9996309,0.0000783027,0.0000405424,0.00003082368,0.0000262836,0.0001931352],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6843646,0.1394275,0.002872129,0.001424446,0.0007233333,0.0004427612,0.0001984517,0.002202295,0.06737342,0.0008069615,0.003777332,0.09638677],"study_design_scores_gemma":[0.4729173,0.5179393,0.002245083,0.00003479688,0.0001920579,0.0001552518,0.0000330852,0.0008727864,0.003473506,0.000157876,0.001961877,0.00001711184],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919649,0.001752416,0.0007448631,0.000449301,0.0002161872,0.003016834,0.0004866153,0.0000647548,0.0013041],"genre_scores_gemma":[0.9810816,0.001611712,0.002741878,0.001121521,0.0003963217,0.005286086,0.001337269,0.0000217993,0.006401724],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004563351,"threshold_uncertainty_score":0.01526594,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03675464115779743,"score_gpt":0.3656061864297622,"score_spread":0.3288515452719648,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}